DOJ Updates Marijuana Classification Policy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: stocktwits
- Policy Change Context: The U.S. Department of Justice has formally proposed reclassifying state-licensed medical marijuana from Schedule I to Schedule III, which, while not legalizing marijuana, reduces regulatory hurdles and offers tax relief for licensed operators, expected to enhance medical research and expand access to treatments.
- Market Reaction: Following the announcement, shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma (IGC) fell between 2-5% in morning trading despite previous gains, indicating a cautious market response to the policy change.
- Investor Sentiment: Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish’ with message volumes surging, reflecting optimistic expectations for the cannabis industry's revival, with some users claiming Tilray will become the “king of the U.S. cannabis market.”
- Akanda Corp. Outperformance: In contrast to major cannabis stocks, Akanda Corp. (AKAN) saw a 6% increase, extending a remarkable 215% surge from the previous session, with investors debating whether this explosive rally is driven by optimism over cannabis reclassification or the stock's low float.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 5.030
Low
8.50
Averages
9.57
High
10.00
Current: 5.030
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. Its adult-use portfolio offers a range of products, from flowers to beverages. Its beverage-alcohol portfolio includes a selection of craft beer, spirits, and beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Brands Expands International Market Presence Amidst Financial Challenges
- Revenue Structure Analysis: Tilray Brands' financial data indicates that its cannabis and wellness divisions accounted for 38% of fiscal 2025 revenue, with the cannabis segment generating $196.9 million in sales in the first nine months, contributing 44% of gross profit, highlighting its significance in the company's profitability structure.
- International Market Contribution: Nearly three-quarters of Tilray's sales come from markets outside the U.S., particularly Canada and EMEA, where regulations are more lenient, driving sales growth, despite challenges from complex regulations and declining sales in the U.S. market.
- Financial Performance Improvement: Although Tilray reported a loss of $67.2 million this year, this figure represents a significant reduction from the $913.5 million loss in the previous year, indicating progress in cost control and operational optimization.
- Future Growth Potential: To achieve profitability, Tilray must continue to drive revenue growth in the Canadian and EMEA markets, especially given the current underperformance in the U.S. market, making international expansion a key to its strategic success.
See More
Trulieve to Uplist on NYSE Amid Regulatory Changes
- Listing Milestone: Trulieve is set to begin trading on the NYSE under the symbol TRLV on Wednesday, with CEO Kim Rivers calling it a 'historic milestone' that signifies the company's successful restructuring in the medical cannabis sector, which is expected to attract more investor attention.
- Optimistic Industry Outlook: AdvisorShares noted that the rescheduling of medical marijuana could enhance earnings, cash flow, and capital access across the industry, particularly ahead of the upcoming DEA hearing, which has heightened market sentiment.
- Strong ETF Performance: As of May 31, the AdvisorShares Pure US Cannabis ETF (MSOS) delivered a remarkable 103.7% one-year net asset value return, significantly outperforming the North American Marijuana Index's 36.9% and the S&P 500's 29.8%, reflecting strong investor interest in cannabis stocks.
- Increased Financing Opportunities: With the implementation of tax deductions for medical marijuana products, Cresco Labs secured a $50 million revolving credit facility, with the CEO stating that this provides a powerful non-dilutive financing tool to support future uplisting plans.
See More
Tilray Brands Sees Growth in International Markets
- International Market Contribution: Nearly 75% of Tilray Brands' sales come from international markets, highlighting their relative ease in navigating U.S. state regulations, which provides a more stable revenue source for the company.
- Cannabis Division Performance: The cannabis segment generated $196.9 million in sales for the first nine months of fiscal 2025, accounting for 31% of total sales and contributing $75.4 million in gross profit, making it the largest profit source for the company and demonstrating its competitive edge in global markets.
- Improved Financial Condition: Although Tilray reported a loss of $67.2 million this fiscal year, this figure is a significant improvement from the $913.5 million loss in the previous year, indicating progress in cost control and operational optimization.
- Regional Sales Growth: Sales growth in Canada and EMEA markets is notable, reflecting the effectiveness of Tilray's market expansion strategies in these regions, while the U.S. market faces declining sales, emphasizing the company's future growth focus on these areas.
See More
Tilray's Brewdog Acquisition Faces Challenges
- Acquisition Context: Tilray acquired Brewdog's UK business for approximately $44 million, despite the latter's sales plummeting by 22.5%, indicating that Tilray may have stepped into a troubled asset.
- Market Share Analysis: While Brewdog holds nearly 50% of the craft beer market in the UK, its sharp decline in sales and volumes could negatively impact Tilray's overall performance, especially during the integration phase.
- Strategic Shift: Tilray is attempting to transition from a marijuana company to a global lifestyle and consumer packaged goods firm, with the Brewdog acquisition being part of its diversification strategy, albeit with high risks and uncertainties.
- Investment Risks: Currently undergoing a significant business overhaul due to underwhelming early investments in marijuana, Tilray's acquisition of Brewdog may lead to weak sales in the short term, suggesting that conservative investors should approach with caution.
See More
Tilray Acquires Brewdog to Expand Business Beyond Marijuana
- Strategic Business Shift: Tilray aims to transform from a marijuana-focused company to a global lifestyle and consumer packaged goods firm by acquiring Brewdog, despite its stock plummeting over 95% due to underperformance in the cannabis sector.
- Acquisition Cost Insight: The acquisition of Brewdog's UK operations cost Tilray approximately $44 million, and while the US side's cost remains undisclosed, it is unlikely to be substantial given Tilray's relatively small size.
- Market Performance Challenges: Brewdog's sales have dropped by 22.5% since the sales process began, posing significant challenges for Tilray and indicating potential difficulties in integration, with weak sales trends expected in the short term.
- Brand Integration Expectations: Although Brewdog's market share has declined, it still holds nearly 50% of the craft beer market in the UK, and Tilray will need time to integrate these brands and develop strategies for a successful business transformation.
See More
Cannabis Reclassification Benefits Industry Players
- Industry Transformation: The DOJ's reclassification of medical marijuana to Schedule III allows cannabis companies to take standard business deductions, which is expected to significantly enhance profitability and attract more investments into the sector.
- Strong Financial Performance: Green Thumb Industries reported first-quarter revenue of $300.2 million, a 7.4% year-over-year increase, with earnings per share of $0.07, reflecting a 75% growth, showcasing its financial discipline and strengthening its competitive position in the market.
- Expansion Potential: Tilray has substantial potential for expansion in the U.S., particularly in the beverage market, as regulatory changes will enable it to leverage its international success to quickly enter the U.S. market, likely driving revenue growth.
- Debt Management Improvement: Tilray successfully reduced its total debt by 6% to $549 million in the third quarter while reaffirming its full-year adjusted EBITDA guidance of $62 million to $72 million, demonstrating operational effectiveness and financial health.
See More
Tilray Brands Expands International Market Presence Amidst Financial Challenges
- Revenue Structure Analysis: Tilray Brands' financial data indicates that its cannabis and wellness divisions accounted for 38% of fiscal 2025 revenue, with the cannabis segment generating $196.9 million in sales in the first nine months, contributing 44% of gross profit, highlighting its significance in the company's profitability structure.
- International Market Contribution: Nearly three-quarters of Tilray's sales come from markets outside the U.S., particularly Canada and EMEA, where regulations are more lenient, driving sales growth, despite challenges from complex regulations and declining sales in the U.S. market.
- Financial Performance Improvement: Although Tilray reported a loss of $67.2 million this year, this figure represents a significant reduction from the $913.5 million loss in the previous year, indicating progress in cost control and operational optimization.
- Future Growth Potential: To achieve profitability, Tilray must continue to drive revenue growth in the Canadian and EMEA markets, especially given the current underperformance in the U.S. market, making international expansion a key to its strategic success.
See More
Trulieve to Uplist on NYSE Amid Regulatory Changes
- Listing Milestone: Trulieve is set to begin trading on the NYSE under the symbol TRLV on Wednesday, with CEO Kim Rivers calling it a 'historic milestone' that signifies the company's successful restructuring in the medical cannabis sector, which is expected to attract more investor attention.
- Optimistic Industry Outlook: AdvisorShares noted that the rescheduling of medical marijuana could enhance earnings, cash flow, and capital access across the industry, particularly ahead of the upcoming DEA hearing, which has heightened market sentiment.
- Strong ETF Performance: As of May 31, the AdvisorShares Pure US Cannabis ETF (MSOS) delivered a remarkable 103.7% one-year net asset value return, significantly outperforming the North American Marijuana Index's 36.9% and the S&P 500's 29.8%, reflecting strong investor interest in cannabis stocks.
- Increased Financing Opportunities: With the implementation of tax deductions for medical marijuana products, Cresco Labs secured a $50 million revolving credit facility, with the CEO stating that this provides a powerful non-dilutive financing tool to support future uplisting plans.
See More
Tilray Brands Sees Growth in International Markets
- International Market Contribution: Nearly 75% of Tilray Brands' sales come from international markets, highlighting their relative ease in navigating U.S. state regulations, which provides a more stable revenue source for the company.
- Cannabis Division Performance: The cannabis segment generated $196.9 million in sales for the first nine months of fiscal 2025, accounting for 31% of total sales and contributing $75.4 million in gross profit, making it the largest profit source for the company and demonstrating its competitive edge in global markets.
- Improved Financial Condition: Although Tilray reported a loss of $67.2 million this fiscal year, this figure is a significant improvement from the $913.5 million loss in the previous year, indicating progress in cost control and operational optimization.
- Regional Sales Growth: Sales growth in Canada and EMEA markets is notable, reflecting the effectiveness of Tilray's market expansion strategies in these regions, while the U.S. market faces declining sales, emphasizing the company's future growth focus on these areas.
See More
Tilray's Brewdog Acquisition Faces Challenges
- Acquisition Context: Tilray acquired Brewdog's UK business for approximately $44 million, despite the latter's sales plummeting by 22.5%, indicating that Tilray may have stepped into a troubled asset.
- Market Share Analysis: While Brewdog holds nearly 50% of the craft beer market in the UK, its sharp decline in sales and volumes could negatively impact Tilray's overall performance, especially during the integration phase.
- Strategic Shift: Tilray is attempting to transition from a marijuana company to a global lifestyle and consumer packaged goods firm, with the Brewdog acquisition being part of its diversification strategy, albeit with high risks and uncertainties.
- Investment Risks: Currently undergoing a significant business overhaul due to underwhelming early investments in marijuana, Tilray's acquisition of Brewdog may lead to weak sales in the short term, suggesting that conservative investors should approach with caution.
See More
Tilray Acquires Brewdog to Expand Business Beyond Marijuana
- Strategic Business Shift: Tilray aims to transform from a marijuana-focused company to a global lifestyle and consumer packaged goods firm by acquiring Brewdog, despite its stock plummeting over 95% due to underperformance in the cannabis sector.
- Acquisition Cost Insight: The acquisition of Brewdog's UK operations cost Tilray approximately $44 million, and while the US side's cost remains undisclosed, it is unlikely to be substantial given Tilray's relatively small size.
- Market Performance Challenges: Brewdog's sales have dropped by 22.5% since the sales process began, posing significant challenges for Tilray and indicating potential difficulties in integration, with weak sales trends expected in the short term.
- Brand Integration Expectations: Although Brewdog's market share has declined, it still holds nearly 50% of the craft beer market in the UK, and Tilray will need time to integrate these brands and develop strategies for a successful business transformation.
See More
Cannabis Reclassification Benefits Industry Players
- Industry Transformation: The DOJ's reclassification of medical marijuana to Schedule III allows cannabis companies to take standard business deductions, which is expected to significantly enhance profitability and attract more investments into the sector.
- Strong Financial Performance: Green Thumb Industries reported first-quarter revenue of $300.2 million, a 7.4% year-over-year increase, with earnings per share of $0.07, reflecting a 75% growth, showcasing its financial discipline and strengthening its competitive position in the market.
- Expansion Potential: Tilray has substantial potential for expansion in the U.S., particularly in the beverage market, as regulatory changes will enable it to leverage its international success to quickly enter the U.S. market, likely driving revenue growth.
- Debt Management Improvement: Tilray successfully reduced its total debt by 6% to $549 million in the third quarter while reaffirming its full-year adjusted EBITDA guidance of $62 million to $72 million, demonstrating operational effectiveness and financial health.
See More
